Safety and immunogenocity of a novel combined Haemophilus influenzae type b–Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old

References

• Watt JP, Wolfson LJ, O'Brien KL, Henkle E, Deloria-Knoll M, McCall N, Lee E, Levine OS, Hajjeh R, Mulholland K, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009; 374:903-11; PMID:19748399; http://dx.doi.org/10.1016/S0140-6736(09)61203-4
   PubMed Web of Science ®Google Scholar
• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol 2012; 799:1-20; PMID:21993636; http://dx.doi.org/10.1007/978-1-61779-346-2_1
   PubMedGoogle Scholar
• Nadel S. Prospects for eradication of meningococcal disease. Arch Dis Childhood 2012; 97:993-8; PMID:22984187; http://dx.doi.org/10.1136/archdischild-2012-302036
   PubMed Web of Science ®Google Scholar
• Su LY, Huang RN, Wang C, Zhang XC. Epideiology of Meningococcal Disease in Chengdu,1950-2008 (in Chinese). J Prev Med Inf 2010; 26:38-42
   Google Scholar
• Hu XJ, Li XW, Ji YD, Xi W, Gao LH. Study on periodically prevaclent features for epidemic cerebrospinal meningitis in China (In Chinese). J Chin Epidemiol 1991; 12:136-9.
   Google Scholar
• Shao Z, Li W, Ren J, Liang X, Xu L, Diao B, Li M, Lu M, Ren H, Cui Z, et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. Lancet 2006; 367:419-23; PMID:16458767; http://dx.doi.org/10.1016/S0140-6736(06)68141-5
   PubMed Web of Science ®Google Scholar
• Xu XH, Ye Y, Hu LF, Jin YH, Jiang QQ, Li JB. Emergence of serogroup C meningococcal disease associated with a high mortality rate in Hefei, China. BMC Infect Dis 2012; 12:205; PMID:22943188; http://dx.doi.org/10.1186/1471-2334-12-205
   PubMedGoogle Scholar
• Li J, Li Y, Shao Z, Li L, Yin Z, Ning G, Xu L, Luo H. Prevalence of meningococcal meningitis in China from 2005 to 2010. Vaccine 2014.
   Web of Science ®Google Scholar
• Li G, Zhang H, Zhou W, Ye Q, Li F, Wang H, Hou Q, Xu Y, Ma X, Tan Y, et al. Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization. Vaccine 2010; 28:4215-23; PMID:20399240; http://dx.doi.org/10.1016/j.vaccine.2010.03.061
   PubMed Web of Science ®Google Scholar
• Ministry of Health. Expanded programmer on immunization in China. Available from: http://www.gov.cn/gzdt/2008-02/19/content_893572.htm. Accessed February 19, 2008.
   Google Scholar
• Chandran A, Watt JP, Santosham M. Prevention of Haemophilus influenzae type b disease: past success and future challenges. Exp Rev Vaccines 2005; 4:819-27; PMID:16372878; http://dx.doi.org/10.1586/14760584.4.6.819
   PubMed Web of Science ®Google Scholar
• Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatric Infect Dis J 2004; 23:S274-9; PMID:15597069
   PubMedGoogle Scholar
• Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 2009; 27 Suppl 2:B20-9; PMID:19477053; http://dx.doi.org/10.1016/j.vaccine.2009.04.067
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2007; 31:101-7; PMID:17168998; http://dx.doi.org/10.1111/j.1574-6976.2006.00053.x
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Maechler G, Habermehl P, Knuf M, Saenger R, Begg N, Boutriau D. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin Vaccine Immunol 2007; 14:426-34; PMID:17287313; http://dx.doi.org/10.1128/CVI.00377-06
   PubMedGoogle Scholar
• Bryant KA, Marshall GS. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers. Exp Rev Vaccines 2011; 10:941-50; PMID:21806393; http://dx.doi.org/10.1586/erv.11.90
   PubMed Web of Science ®Google Scholar
• Zhu FC, Liang ZL, Li XL, Ge HM, Meng FY, Mao QY, Zhang YT, Hu YM, Zhang ZY, Li JX, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2013; 381:1037-45; PMID:23352749; http://dx.doi.org/10.1016/S0140-6736(12)61764-4
   PubMed Web of Science ®Google Scholar
• Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, Fischbach T, Zinke H, Pankow-Culot H, Papaevangelou V, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011; 29:4264-73; PMID:21420417; http://dx.doi.org/10.1016/j.vaccine.2011.03.009
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27:161-8; PMID:18834910; http://dx.doi.org/10.1016/j.vaccine.2008.08.075
   PubMed Web of Science ®Google Scholar
• Pace D, Snape M, Westcar S, Oluwalana C, Yu LM, Begg N, Wysocki J, Czajka H, Maechler G, Boutriau D, et al. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. Arch Dis Childhood 2008; 93:963-70; PMID:18463125; http://dx.doi.org/10.1136/adc.2007.136036
   PubMed Web of Science ®Google Scholar
• Gatchalian S, Palestroque E, De Vleeschauwer I, Han HH, Poolman J, Schuerman L, Dobbelaere K, Boutriau D. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. Inter J Infect Dis 2008; 12:278-88; PMID:17981067; http://dx.doi.org/10.1016/j.ijid.2007.08.007
   PubMed Web of Science ®Google Scholar
• Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clinical Investigation 1975; 56:1536-47; PMID:1202084; http://dx.doi.org/10.1172/JCI108235
   PubMed Web of Science ®Google Scholar
• Richmond P, Kaczmarski E, Borrow R, Findlow J, Clark S, McCann R, Hill J, Barker M, Miller E. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000; 181:761-4; PMID:10669372; http://dx.doi.org/10.1086/315284
   PubMed Web of Science ®Google Scholar
• MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. Jama 1998; 280:1685-9; PMID:9832000; http://dx.doi.org/10.1001/jama.280.19.1685
   PubMed Web of Science ®Google Scholar
• Jokhdar H, Borrow R, Sultan A, Adi M, Riley C, Fuller E, Baxter D. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol 2004; 11:83-8; PMID:14715549
   PubMedGoogle Scholar
• Broker M, Veitch K. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine. Travel Med Infect Dis 2010; 8:47-50; PMID:20188306; http://dx.doi.org/10.1016/j.tmaid.2009.12.001
   PubMed Web of Science ®Google Scholar
• SFDA. The guideline for rating scales of adverse reaction of clinical trials of preventive vaccines.Available at: http://www.sda.gov.cn/WS01/CL0055/9350_5.html. Accessed October 14, 2005.
   Google Scholar
• NIH. Division of microbiology and infectious diseases pediatric toxicity table-DRAFT. Available at: http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Pages/toxtables.aspx. Accessed November 11, 2007.
   Google Scholar
• Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, Arhin FF, Devi SJ, Frasch CE, Huang JC, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997; 4:156-67; PMID:9067649
   PubMedGoogle Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine 2005; 23:2222-7; PMID:15755600; http://dx.doi.org/10.1016/j.vaccine.2005.01.051
   PubMed Web of Science ®Google Scholar
• Inadvertent misadministration of meningococcal conjugate vaccine–United States, June-August 2005. MMWR Morb Mortal Wly Rep 2006; 55:1016-7; PMID:16988640
   PubMedGoogle Scholar
• Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immu 2001; 69:1568-73; PMID:11179328; http://dx.doi.org/10.1128/IAI.69.3.1568-1573.2001
   PubMed Web of Science ®Google Scholar
• Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100; PMID:6602191; http://dx.doi.org/10.1093/infdis/147.6.1100
   PubMed Web of Science ®Google Scholar
• Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1984; 149:1034-5; PMID:6610714; http://dx.doi.org/10.1093/infdis/149.6.1034
   PubMed Web of Science ®Google Scholar